A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study)
Study sponsor: Relay Therapeutics, Inc. · RLAY
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2031-07Estimated
Enrollment · participants277Estimated
Source updated2026-11-19Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.